Candel Therapeutics Inc
CADL6.318USD
+0.028+0.45%
Horário de mercado （ET）Cotações atrasadas em 15 min
311.15MValor de mercado
PerdaP/L TTM
Mais detalhes de Candel Therapeutics Inc Empresa
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Informações da empresa
Código da empresaCADL
Nome da EmpresaCandel Therapeutics Inc
Data de listagemJul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
Número de funcionários38
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 27
Endereço117 Kendrick Street,
CidadeNEEDHAM
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02494
Telefone16179165445
Sitehttps://www.candeltx.com/
Código da empresaCADL
Data de listagemJul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Seshu Tyagarajan, Ph.D.
Ms. Seshu Tyagarajan, Ph.D.
Chief Technical and Development Officer
Chief Technical and Development Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. W. Garrett Nichols, M.D.
Dr. W. Garrett Nichols, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Detalhamento da receita
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 24 de mai
Atualizado em: sáb, 24 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Tipos de investidores
Investidores
Proporção
Investment Advisor
29.01%
Individual Investor
16.48%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.99%
Corporation
2.48%
Research Firm
0.64%
Bank and Trust
0.09%
Pension Fund
0.02%
Insurance Company
0.02%
Other
39.06%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
162
31.98M
60.95%
-104.17K
2025Q1
160
30.10M
67.51%
-1.81M
2024Q4
131
27.38M
62.24%
+9.09M
2024Q3
115
17.10M
48.26%
-703.44K
2024Q2
98
16.89M
49.23%
+872.97K
2024Q1
67
14.85M
50.59%
-1.40M
2023Q4
65
14.94M
51.56%
-1.48M
2023Q3
68
15.61M
53.96%
-846.00K
2023Q2
65
15.70M
54.30%
-590.47K
2023Q1
64
16.17M
55.93%
-250.07K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
7.09M
13.5%
+766.60K
+12.13%
Mar 31, 2025
Manning (Paul B.)
2.82M
5.38%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.92%
+428.26K
+19.90%
Jun 25, 2025
Baker Bros. Advisors LP
2.44M
4.64%
-544.79K
-18.27%
Mar 31, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.61%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.49%
-690.05K
-22.65%
Apr 21, 2025
The Vanguard Group, Inc.
1.74M
3.31%
+396.95K
+29.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
3.06%
+515.63K
+47.27%
Mar 31, 2025
BKB Growth Investments LLC
1.30M
2.48%
+750.00K
+135.44%
Apr 21, 2025
Portolan Capital Management, L.L.C.
881.18K
1.68%
+127.44K
+16.91%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
0.17%
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.05%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção0.17%
Vanguard US Momentum Factor ETF
Proporção0.08%
iShares Micro-Cap ETF
Proporção0.05%
iShares Russell 2000 ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
